Home LiteratureArticle Details
PMID: 1744995 Published · ppublish English Journal Article

Nilvadipine, a new calcium channel blocker, reduces ischemic brain injury in rats.

Japanese journal of pharmacology ·Vol. 56 ·No. 4 ·1991-08-00 ·Pages 547-50

Takakura S, Susumu T, Satoh H, Mori J, Shiino A, Handa J

Abstract

The effects of nilvadipine, a dihydropyridine type calcium channel blocker, on cerebral infarction induced by focal brain ischemia was studied in rats. The area of infarction was measured 24 hr after occlusion of the middle cerebral artery (MCA) in spontaneously hypertensive rats using triphenyltetrazolium chloride. Nilvadipine, given immediately after MCA occlusion, reduced the area of infarction significantly at doses of 0.32 mg/kg (i.p.) and 3.2, 10 and 32 mg/kg (p.o.). Nicardipine suppressed the area of infarction at a dose of 32 mg/kg (p.o.). The results suggest that nilvadipine is effective against ischemic brain injury.

MeSH Terms
Animals Brain Ischemia/drug therapy Calcium Channel Blockers/therapeutic use Cerebral Infarction/drug therapy,etiology Nicardipine/administration & dosage,therapeutic use Nifedipine/analogs & derivatives,therapeutic use Rats Rats, Inbred SHR
Chemicals
Calcium Channel Blockers nilvadipine Nicardipine Nifedipine
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Takakura S
Department of Pharmacology, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan.
Susumu T
Satoh H
Mori J
Shiino A
Handa J
Article Info
Journal
Japanese journal of pharmacology
Abbr.
Jpn J Pharmacol
ISSN
0021-5198
Published
1991-08-00
Pages
547-50
Language
English
Region
Japan
NLM ID
2983305R
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com